MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ehjcvp/pvaf005

Медицинская библиотека · European heart journal. Cardiovascular pharmacotherapy · 2025

Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis.

Zorman Mark J, Vibhishanan Jonathan, Dangas Katerina, Castle James, Li Ka Hou Christien, Coronelli Marco, Eastwick-Jones Kate, Swan Alexander, Johnson Nicky, Choksey Anurag, Yan Helen, Scott Sam G C, Henry Matthew, Cassar Mark Philip, Barnes Cara, Ferreira-Martins Joao, Newton James, Dawkins Sam, Alkhouli Mohamad, Rihal Charanjit, Eleid Mackram F, Pislaru Sorin V, Guerrero Mayra E, Ordonez-Mena Jose, Cahill Thomas J

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

AIMS: Transcatheter mitral valve replacement (TMVR) has become a feasible alternative to surgical mitral valve replacement (SMVR) in selected patients at high surgical risk. The risk of valve thrombosis following SMVR and TMVR, and the optimal antithrombotic therapy following these procedures, remains uncertain. We aimed to compare the incidence of bioprosthetic mitral valve thrombosis (bMVT) after SMVR and TMVR, and the incidence of bMVT between patients on different antithrombotic regimens.

METHODS AND

RESULTS

A literature search of Medline, Embase, and Cochrane Library was performed between January 2000 and August 2024. Random-effects models were used to derive pooled estimates of the incidence of bMVT in the absence of prior or active endocarditis and valve thrombosis. A total of 47 studies (6170 patients, total follow-up 9541.8 patient-years) were eligible for inclusion. The overall incidence of bMVT was 5.05 [95% confidence interval (CI) 3.18-8.01, I2 = 82%] per 100-patient-years. Subclinical bMVT was more common than clinically significant bMVT: incidence 19.11 vs. 7.91 per 100-patient-years, adjusted incidence rate ratio (aIRR) 4.62 (95% CI 1.39-15.36), P = 0.012. bMVT was numerically more common after TMVR than SMVR, but the comparison was not statistically significant: incidence 7.03 vs. 0.58 per 100-patient-years, aIRR 2.19 (95% CI 0.72-6.72), P = 0.170. Patients on vitamin-K antagonists (VKA) had a lower incidence of bMVT than patients on direct oral anticoagulants (DOAC; incidence 5.72 vs. 17.08, aIRR 0.31, 95% CI 0.13-0.73, P = 0.007).

CONCLUSIONS

bMVT is not uncommon, with numerically higher incidence in transcatheter compared to surgical valves, but the comparison was not statistically significant. VKAs are associated with a lower incidence of bMVT compared to DOACs.

Для цитирования: Zorman Mark J, Vibhishanan Jonathan, Dangas Katerina, Castle James, Li Ka Hou Christien, Coronelli Marco, Eastwick-Jones Kate, Swan Alexander, Johnson Nicky, Choksey Anurag, Yan Helen, Scott Sam G C, Henry Matthew, Cassar Mark Philip, Barnes Cara, Ferreira-Martins Joao, Newton James, Dawkins Sam, Alkhouli Mohamad, Rihal Charanjit, Eleid Mackram F, Pislaru Sorin V, Guerrero Mayra E, Ordonez-Mena Jose, Cahill Thomas J. Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis.. European heart journal. Cardiovascular pharmacotherapy. 2025. DOI: 10.1093/ehjcvp/pvaf005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.